News
Fact Check: What Is True in the Viral Claims About Cancer Vaccine Pricing
A widely shared clip argues personalized cancer vaccines are overpriced, built on old technology, and paid for by taxpayers. We checked each claim against the trial results, the pricing figure being quoted, and the published record of public funding.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
The short version
A clip has been circulating on Instagram since 2 September 2026. It makes three arguments about personalized cancer vaccines. That they cost too much. That the technology behind them is older than the coverage suggests. And that the public paid for much of that technology, so the public should get more from it.
Two of those arguments are broadly supportable. The pricing one is being repeated in a form that is not accurate, and the number most people are quoting is not a price at all.
Nothing on this page is a view about whether the treatment works. That is covered in what the melanoma trial found.
Who is speaking, and where the clip comes from
The clip was posted on 2 September 2026 by the account @metav3rse and credited in its caption to the All-In Podcast. The speaker is David Friedberg, one of the podcast's four regular hosts.
His background. By the podcast's own description, Friedberg is CEO, chairman and co-founder of Ohalo Genetics, an agricultural genetics company. He also founded The Production Board, a venture firm that builds and invests in food, agriculture and life sciences businesses. He earlier founded The Climate Corporation, an agricultural data company later acquired by Monsanto, and worked at Google before that. He attended the University of California, Berkeley. He posts as @friedberg on X, the account the podcast lists for him.
What that means for weight. Friedberg is an investor and operator in life sciences, not a physician, oncologist or health economist. He is a knowledgeable commentator on how biotechnology gets funded and commercialised, which is the subject he is speaking about here. He is not a clinical authority on melanoma treatment, and the clip is not medical advice. Readers should weight his funding-and-pricing arguments differently from clinical questions about whether the therapy should be used.
His positioning. The argument in the clip is a market-structure argument, not a scientific objection. He is not disputing that the treatment works or arguing against mRNA medicine. The caption frames the position this way. Public research money seeded much of the technology. It has ended up concentrated in a few companies that can set a high price. So the public should get more of the benefit. That is a familiar line of argument in biotech investing circles, and it is a policy view rather than a finding.
Where to hear it for yourself
The segment comes from All-In Podcast episode #287, "Nvidia's Historic Quarter, SaaS Comeback, Bessent vs Druck, America's Debt Crisis, Cancer Vaccine," published 28 August 2026. The relevant chapter is titled "Science Corner: Moderna's mRNA cancer vaccine" and begins at 1:22:52.
- Video: youtube.com/watch?v=1u5dMAKl_ks (jump to 1:22:52)
- Audio: Spotify
- Episode index: allin.com/episodes
What we could and could not verify
We identified the episode and the chapter, but were not able to obtain a verified transcript of the audio.
For that reason this page contains no quotations from Friedberg and attributes no specific wording to him. The claims checked below are the ones written in the Instagram post's own caption, which is a paraphrase by the account that posted the clip, not by Friedberg or the podcast. If the clip is edited, or the caption paraphrases loosely, the claims may not match what he said in full.
If you want to know what Friedberg actually said, the chapter is linked above and runs a few minutes. Nothing on this page is a quotation from him, and no sentence here should be read as his position. What follows checks the claims as the caption stated them, against the published evidence.
Claim 1: "These vaccines cost around half a million dollars"
Misleading, and the number is not a price.
The figure travelling with this story is $475,000. It comes from a valuation model published by the investment bank William Blair after the Phase 3 results were announced. It is an assumed US wholesale acquisition cost, arrived at by benchmarking against approved CAR-T cell therapies — not a price anyone has announced, and not a costing of what the treatment takes to make.
Three further points get lost in the retelling:
- It is not a per-injection cost. The regimen is up to nine doses over roughly a year. Dividing the assumed figure gives about $52,800 per dose, though that arithmetic is not meaningful either.
- It is not the whole bill. The therapy is given with pembrolizumab, which carries its own list price of about $220,900 a year. A combined list price would be higher still.
- List price is not what patients pay. What reaches a patient depends on insurance, rebates and coverage rules — and none of that exists yet, because the treatment is not approved.
There is a real affordability question here. It is just not answered by a number that has not been set.
Claim 2: "The technology is not as new as it is presented"
Substantially true.
Neither half of this treatment is new.
The idea of targeting neoantigens — the altered proteins that cancer mutations produce — has been worked on in academic and government labs for decades, including at the NCI. The first personalized neoantigen vaccine trials in people were published in 2017.
The mRNA delivery method is older still in research terms. The chemical modification that made therapeutic mRNA practical was published in 2005. Katalin Karikó and Drew Weissman did that work at the University of Pennsylvania. It won the 2023 Nobel Prize in Medicine.
What is new is the Phase 3 evidence. The INTerpath-001 trial was reported on 19 August 2026. It randomised 1,137 patients with completely resected stage IIB–IV melanoma. It met its primary endpoint, recurrence-free survival. It also met its key secondary endpoint, distant metastasis-free survival. That is the first Phase 3 result of its kind. The underlying science is old; the proof that it does something in a large randomised trial is not.
Claim 3: "Public money paid for the research"
True in part, and quantified — but it does not cover everything.
For the mRNA platform, there is a published figure. A retrospective cohort study in The BMJ in 2023 found the US government invested at least $337 million in mRNA vaccine research and development between 1985 and 2019, split across NIH ($116m), BARDA ($148m) and the Department of Defense ($72m). A further $31.6 billion was spent during the pandemic, though 92% of that was vaccine purchases rather than research.
That study is about COVID vaccines, not cancer vaccines. It is the right evidence for "the platform was publicly seeded" and the wrong evidence for "the public paid for this cancer product." The individualised manufacturing, the neoantigen-selection software, and a 1,137-patient Phase 3 trial were company-funded, and those are the expensive parts.
Both things can be true: the foundation was substantially public, and the product on top of it was not.
Claim 4: "It should be more widely available instead of controlled by a few companies"
This is a policy position, not a factual claim — but the mechanism people reach for is weaker than assumed.
The lever usually named is march-in rights under the Bayh-Dole Act, which lets the government relicense inventions made with federal funding. A draft NIST framework proposed letting price factor into that decision. As of December 2025, GAO reported that NIST had not finalised it and had no timeline, citing a lack of interagency consensus. Of roughly a dozen march-in requests since 1980, most about drug prices, agencies have granted none.
GAO also noted analyses finding that price-based march-in would reach only a small number of drugs, because most pharmaceutical patents sit outside Bayh-Dole's scope.
What none of this changes for patients
Intismeran autogene is not approved by the FDA. Merck and Moderna have said they will discuss filing with regulators. Outside a clinical trial, it cannot currently be prescribed at any price.
The practical barriers described in how an individualized neoantigen therapy is made — the need for surgical tumour tissue, the weeks of manufacturing, the fact that each batch treats one person — are separate from the pricing argument and are not solved by it.
If you or someone you care for has melanoma and this coverage prompted a question, the useful next step is asking a treating oncologist whether a trial is open, not tracking the price debate. Finding a clinical trial explains how.
Sources
- https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
- https://www.bmj.com/content/380/bmj-2022-073747
- https://www.gao.gov/products/gao-26-107885
- https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines
- https://www.youtube.com/watch?v=1u5dMAKl_ks (All-In Podcast episode #287, 28 August 2026; cancer vaccine chapter at 1:22:52)
- https://open.spotify.com/episode/2Ygvem599PTPNf2H8xHU6x
- https://allin.com/episodes
- https://allin.com/about (host biographies)
- https://www.instagram.com/reel/DcyG8VBho3_/ (@metav3rse, 2 September 2026)
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Melanoma. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.